News

Warsaw, Poland and Gothenburg, Sweden – 24 September 2026 – Bramble Bio, the cell and gene therapy contract development and manufacturing organisation, and VERIGRAFT AB, a Swedish clinical-stage biotechnology company developing personalised, fully biological tissue therapies, today announced a manufacturing partnership supporting the clinical development of VERIGRAFT’s lead product candidate, P-TEV. Under the agreement, VERIGRAFT […]

Dystrogen Therapeutics and Bramble Bio Announce Strategic Manufacturing Partnership to Advance DT-DEC01 for Duchenne Muscular Dystrophy Dystrogen Therapeutics, a biotechnology company dedicated to developing advanced therapies for rare neuromuscular diseases, today announced a strategic partnership with Bramble Bio to manufacture its lead candidate DT-DEC01. This highly innovative therapy leverages the ex-vivo fusion of allogeneic human […]

25 Sep 2025 – Bramble Bio today announced a strategic manufacturing partnership with Keli Therapeutics to advance KELI-101, a novel cell therapy targeting acute kidney injury (AKI) following cardiac bypass surgery (CPB-AKI). This serious inflammatory complication often progresses to chronic kidney disease, leaving patients with limited treatment options. By pairing Keli’s breakthrough therapy with Bramble […]

LEIPZIG, GERMANY – July 29, 2025 – BIONCaRT GmbH, a biotech company focused on developing cell therapies for orthopedic diseases, today announced strategic collaborations with Bramble Bio, a Contract Development and Manufacturing Organization (CDMO) specializing in cell and gene therapies and part of the FamiCord AG, and the Fraunhofer Institute for Cell Therapy and Immunology […]